HC Wainwright Has Strong Estimate for AVTX FY2026 Earnings

Key Points

• HC Wainwright raised its FY2026 EPS estimate for Avalo Therapeutics to a loss of $2.43 per share from a projected loss of $2.76, while maintaining a Neutral rating. The revised estimate is also less negative than the analyst consensus loss of $2.79.
• Avalo reported a quarterly loss of $0.34 per share, beating analysts’ expected loss of $0.59 by $0.25. Analysts overall have a Moderate Buy consensus rating and an average price target of $36.82.
• AVTX shares opened at $7.27, near their 52-week low of $6.53 and well below their 50- and 200-day moving averages of $13.24 and $15.80, respectively.

Avalo Therapeutics, Inc. (NASDAQ:AVTX - Free Report) - Analysts at HC Wainwright lifted their FY2026 earnings per share estimates for shares of Avalo Therapeutics in a research report issued on Friday, November 6th. HC Wainwright analyst M. Kapoor now anticipates that the company will post earnings per share of ($2.43) for the year, up from their previous forecast of ($2.76). HC Wainwright has a "Neutral" rating on the stock. The consensus estimate for Avalo Therapeutics' current full-year earnings is ($2.79) per share. HC Wainwright also issued estimates for Avalo Therapeutics' Q4 2026 earnings at ($0.55) EPS, Q1 2027 earnings at ($0.54) EPS, Q2 2027 earnings at ($0.55) EPS, Q3 2027 earnings at ($0.56) EPS, Q4 2027 earnings at ($0.57) EPS and FY2027 earnings at ($2.23) EPS.

A number of other brokerages have also issued reports on AVTX. Oppenheimer set a $16.00 target price on shares of Avalo Therapeutics in a research report on Monday, October 26th. Wall Street Zen upgraded shares of Avalo Therapeutics from a "sell" rating to a "hold" rating in a research report on Saturday. Guggenheim lowered shares of Avalo Therapeutics from a "buy" rating to a "neutral" rating in a research note on Friday, October 23rd. Wedbush decreased their price objective on shares of Avalo Therapeutics from $22.00 to $20.00 and set an "outperform" rating for the company in a report on Friday. Finally, Cantor Fitzgerald reiterated an "overweight" rating on shares of Avalo Therapeutics in a report on Wednesday, September 16th. Eleven analysts have rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, Avalo Therapeutics presently has a consensus rating of "Moderate Buy" and an average target price of $36.82.

Avalo Therapeutics Stock Performance

Shares of NASDAQ AVTX opened at $7.27 on Tuesday. The firm's 50-day simple moving average is $13.24 and its 200 day simple moving average is $15.80. Avalo Therapeutics has a fifty-two week low of $6.53 and a fifty-two week high of $24.27.

Avalo Therapeutics (NASDAQ:AVTX - Get Free Report) last released its quarterly earnings results on Thursday, November 5th. The company reported ($0.34) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.59) by $0.25.

Institutional Trading of Avalo Therapeutics

Several institutional investors and hedge funds have recently added to or reduced their stakes in AVTX. Seven Fleet Capital Management LP boosted its stake in shares of Avalo Therapeutics by 34.3% during the 2nd quarter. Seven Fleet Capital Management LP now owns 770,765 shares of the company's stock worth $14,244,000 after acquiring an additional 196,882 shares in the last quarter. Wellington Management Group LLP acquired a new position in shares of Avalo Therapeutics in the 2nd quarter valued at about $1,945,000. Renaissance Technologies LLC increased its stake in Avalo Therapeutics by 556.4% in the 1st quarter. Renaissance Technologies LLC now owns 120,114 shares of the company's stock valued at $1,793,000 after buying an additional 101,814 shares during the period. DV Trading LLC purchased a new stake in Avalo Therapeutics in the 1st quarter worth approximately $5,376,000. Finally, Sei Investments Co. acquired a new stake in shares of Avalo Therapeutics during the 1st quarter valued at $849,000. 87.06% of the stock is owned by institutional investors and hedge funds.

Insiders Place Their Bets

In related news, CFO Christopher Sullivan sold 12,394 shares of the firm's stock in a transaction dated Wednesday, September 16th. The stock was sold at an average price of $16.33, for a total transaction of $202,394.02. Following the completion of the transaction, the chief financial officer owned 39,900 shares of the company's stock, valued at $651,567. This trade represents a 23.70% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 23,258 shares of company stock worth $395,434 over the last ninety days. Company insiders own 4.46% of the company's stock.

Avalo Therapeutics Company Profile

Avalo Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing therapies for immune-mediated and inflammatory diseases. The company's research and development programs are intended to address conditions with significant unmet medical needs.

Avalo's lead product candidate is AVTX-009, a fully human monoclonal antibody designed to inhibit interleukin-1 beta, an inflammatory cytokine involved in several immune-related disorders. The candidate is being evaluated for potential treatment of hidradenitis suppurativa, a chronic inflammatory skin disease, and other inflammatory conditions.

The company was formerly known as Cerecor Inc and adopted the Avalo Therapeutics name in 2021.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.